[go: up one dir, main page]

WO2011149126A1 - Pharmaceutical composition comprising an anti-inflammatory compound having a tyrosine kinase inhibiting function - Google Patents

Pharmaceutical composition comprising an anti-inflammatory compound having a tyrosine kinase inhibiting function Download PDF

Info

Publication number
WO2011149126A1
WO2011149126A1 PCT/KR2010/003332 KR2010003332W WO2011149126A1 WO 2011149126 A1 WO2011149126 A1 WO 2011149126A1 KR 2010003332 W KR2010003332 W KR 2010003332W WO 2011149126 A1 WO2011149126 A1 WO 2011149126A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
tyrosine kinase
kinase inhibiting
inhibiting function
inflammatory compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2010/003332
Other languages
French (fr)
Korean (ko)
Inventor
양범석
김용주
박태교
우성호
이향숙
김선영
조종운
이홍범
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Science and Technology KIST
Ligachem Biosciences Inc
Original Assignee
Korea Institute of Science and Technology KIST
Legochem Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute of Science and Technology KIST, Legochem Biosciences Inc filed Critical Korea Institute of Science and Technology KIST
Priority to PCT/KR2010/003332 priority Critical patent/WO2011149126A1/en
Priority to EP11786920.6A priority patent/EP2578590B1/en
Priority to JP2013512543A priority patent/JP5613323B2/en
Priority to PCT/KR2011/003873 priority patent/WO2011149288A2/en
Priority to ES11786920.6T priority patent/ES2647586T3/en
Priority to CN201180026042.7A priority patent/CN102971327B/en
Priority to US13/699,970 priority patent/US9062066B2/en
Priority to DK11786920.6T priority patent/DK2578590T3/en
Priority to KR1020127030670A priority patent/KR101478302B1/en
Priority to HUE11786920A priority patent/HUE035589T2/en
Publication of WO2011149126A1 publication Critical patent/WO2011149126A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a pharmaceutical composition which contains an active ingredient in the form of an anti-inflammatory compound having a tyrosine kinase inhibiting function, and the compound according to the present invention can suppress the activities of various tyrosine kinases, and can be used to advantage in the prevention or treatment of inflammatory diseases, autoimmune diseases and the like associated therewith.
PCT/KR2010/003332 2010-05-26 2010-05-26 Pharmaceutical composition comprising an anti-inflammatory compound having a tyrosine kinase inhibiting function Ceased WO2011149126A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
PCT/KR2010/003332 WO2011149126A1 (en) 2010-05-26 2010-05-26 Pharmaceutical composition comprising an anti-inflammatory compound having a tyrosine kinase inhibiting function
EP11786920.6A EP2578590B1 (en) 2010-05-26 2011-05-26 Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing same
JP2013512543A JP5613323B2 (en) 2010-05-26 2011-05-26 Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing the same
PCT/KR2011/003873 WO2011149288A2 (en) 2010-05-26 2011-05-26 Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing same
ES11786920.6T ES2647586T3 (en) 2010-05-26 2011-05-26 Anti-inflammatory compound that has inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing the same
CN201180026042.7A CN102971327B (en) 2010-05-26 2011-05-26 There is the anti-inflammatory compound of multiple tyrosine-kinase enzyme inhibition activity and the pharmaceutical compositions containing these compounds
US13/699,970 US9062066B2 (en) 2010-05-26 2011-05-26 Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same
DK11786920.6T DK2578590T3 (en) 2010-05-26 2011-05-26 ANTI-INFLAMMATORY RELATIONSHIP WITH INHIBITORIAL ACTIVITY AGAINST MULTIPLE TYROSINKINASAS AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
KR1020127030670A KR101478302B1 (en) 2010-05-26 2011-05-26 Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same
HUE11786920A HUE035589T2 (en) 2010-05-26 2011-05-26 Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2010/003332 WO2011149126A1 (en) 2010-05-26 2010-05-26 Pharmaceutical composition comprising an anti-inflammatory compound having a tyrosine kinase inhibiting function

Publications (1)

Publication Number Publication Date
WO2011149126A1 true WO2011149126A1 (en) 2011-12-01

Family

ID=45004106

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/003332 Ceased WO2011149126A1 (en) 2010-05-26 2010-05-26 Pharmaceutical composition comprising an anti-inflammatory compound having a tyrosine kinase inhibiting function

Country Status (1)

Country Link
WO (1) WO2011149126A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492383B1 (en) * 1997-11-11 2002-12-10 Pfizer Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
WO2007056214A2 (en) * 2005-11-02 2007-05-18 Cytovia, Inc N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492383B1 (en) * 1997-11-11 2002-12-10 Pfizer Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
WO2007056214A2 (en) * 2005-11-02 2007-05-18 Cytovia, Inc N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOSCHELLI, D.H. ET AL.: "Inhibition of Src kinase activity by 7-[(2,4-dichloro-5-methoxyphenyl)-amino]-2-heteroaryl-thieno[3,2-b] pyridine-6-carbonitriles", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 15, 2005, pages 4681 - 4684 *

Similar Documents

Publication Publication Date Title
WO2011149288A3 (en) Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing same
WO2012046030A3 (en) Phosphodiesterase inhibitors
WO2011162515A3 (en) Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
WO2008094737A3 (en) Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
HK1210775A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
WO2012021715A3 (en) Stable formulations of linaclotide
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MX2010014041A (en) A crystalline form of posaconazole.
WO2013185082A3 (en) Inhibitors of bruton's tyrosine kinase
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
HK1206726A1 (en) Imidazotriazinone compounds
WO2011106248A3 (en) Trimethoxyphenyl inhibitors of tyrosine kinase
MX2009011952A (en) Compounds and compositions as c-kit and pdgfr kinase inhibitors.
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
WO2012101653A3 (en) Modified release pharmaceutical compositions memantine
NZ745210A (en) Novel 2,3,5-substituted thiophene compound as protein kinase inhibitor
WO2011150457A3 (en) Haematopoietic-prostaglandin d2 synthase inhibitors
WO2011126250A3 (en) Composition containing pde5 inhibitor for relieving skin wrinkles
WO2011121576A3 (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
AU2013208104A8 (en) Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof
WO2014160775A8 (en) Compositions and methods for the treatment of malaria
WO2011159137A3 (en) Novel thiourea or urea derivative, preparation method thereof, and pharmaceutical composition for preventing or treating aids, containing same as active ingredient
WO2011149301A3 (en) A composition comprising the extract of physalis alkekengi var. francheti hort as an active ingredient for preventing and treating inflammatory diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10852212

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 07.03.2013)

122 Ep: pct application non-entry in european phase

Ref document number: 10852212

Country of ref document: EP

Kind code of ref document: A1